Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution

被引:24
作者
Liu, Zhenzhen [1 ]
Feng, Yukun [1 ]
Zhang, Lunhui [1 ]
Li, Guofei [1 ]
Geng, Lulu [1 ]
Cui, Yan [1 ]
Teng, Fei [1 ]
Tang, Xing [1 ]
Bi, Kaishun [1 ]
Chen, Xiaohui [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
关键词
UPLC-MS/MS; Larotaxel; Lipid microsphere; Pharmacokinetics; Tissue distribution; RPR; 109881A; PHASE-I; INTRAVENOUS-INFUSION; DOCETAXEL; EMULSION; FORMULATION; DELIVERY; SYSTEMS; 1-HOUR; CYP3A;
D O I
10.1007/s00280-013-2104-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Larotaxel is a new taxane compound with poor solubility. The aim of this study is to develop a new formulation to locate the poorly soluble drug and compare the pharmacokinetics and tissue distribution of larotaxel-loaded microsphere (LTX-LM) with the solution form larotaxel-solution (LTX-solution). A sensitive and efficient UPLC-MS/MS method was developed and validated for determination of larotaxel in rat plasma and tissues and applied to assess the plasma protein binding, pharmacokinetics, and tissue distribution. Pharmacokinetic study indicated that larotaxel plasma disposition was triphasic, and LTX-LM group had markedly higher AUC, smaller clearance, and lower apparent volume of distribution than the LTX-solution group. The tissue distribution exhibited significant lower uptake of LTX-LM in lung, kidney, heart, muscle, and brain among all the tissues, indicating the advantage of LTX-LM over the solution form in reducing drug precipitation in vivo and toxicity in cardiovascular system and central nervous system. These results suggest that lipid microsphere could be an effective parenteral carrier for LTX delivery in cancer treatment.
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 39 条
[1]
LIPOSOME DISPOSITION INVIVO .6. DELIVERY TO THE LUNG [J].
ABRA, RM ;
HUNT, CA ;
LAU, DT .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (02) :203-206
[2]
Drug interactions in oncology [J].
Beijnen, JH ;
Schellens, JHM .
LANCET ONCOLOGY, 2004, 5 (08) :489-496
[3]
Pharmacokinetic comparisons of Shuang-Huang-Lian with the different combinations of its constitutional herbs [J].
Di, Bin ;
Feng, Nianping ;
Liu, Wenying .
JOURNAL OF ETHNOPHARMACOLOGY, 2006, 107 (03) :401-405
[4]
Alternative drug formulations of docetaxel: a review [J].
Engels, Frederike K. ;
Mathot, Ron A. A. ;
Verweij, Jaap .
ANTI-CANCER DRUGS, 2007, 18 (02) :95-103
[5]
A liquid chromatography-tandem mass spectrometry method for the quantification of PAC-1 in rat plasma [J].
Fang, Li-Na ;
Chen, Xiao-Hui ;
Wang, Qiu-Di ;
Zhang, Di ;
Zhao, Juan-Juan ;
Long, Zhi-Min ;
Gong, Ping ;
Bi, Kai-Shun .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 54 (01) :225-229
[6]
FCDER (Center for Drug Evaluation and Research), 2001, GUID IND BIOAN METH
[7]
Top ten considerations in the development of parenteral emulsions [J].
Floyd, AG .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (04) :134-143
[8]
Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors [J].
Gelmon, KA ;
Latreille, J ;
Tolcher, A ;
Génier, L ;
Fisher, B ;
Forand, D ;
D'Aloisio, S ;
Vernillet, L ;
Daigneault, L ;
Lebecq, A ;
Besenval, M ;
Eisenhauer, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4098-4108
[9]
Gibbs MA, 1999, DRUG METAB DISPOS, V27, P180
[10]
RELATIONSHIPS BETWEEN THE STRUCTURE OF TAXOL ANALOGS AND THEIR ANTIMITOTIC ACTIVITY [J].
GUERITTEVOEGELEIN, F ;
GUENARD, D ;
LAVELLE, F ;
LEGOFF, MT ;
MANGATAL, L ;
POTIER, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (03) :992-998